AU2009220942B2 - Methods of treatment employing prolonged continuous infusion of Belinostat - Google Patents

Methods of treatment employing prolonged continuous infusion of Belinostat Download PDF

Info

Publication number
AU2009220942B2
AU2009220942B2 AU2009220942A AU2009220942A AU2009220942B2 AU 2009220942 B2 AU2009220942 B2 AU 2009220942B2 AU 2009220942 A AU2009220942 A AU 2009220942A AU 2009220942 A AU2009220942 A AU 2009220942A AU 2009220942 B2 AU2009220942 B2 AU 2009220942B2
Authority
AU
Australia
Prior art keywords
prolonged continuous
intravenous infusion
cancer
continuous intravenous
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009220942A
Other languages
English (en)
Other versions
AU2009220942A8 (en
AU2009220942A1 (en
Inventor
Peter Buhl Jensen
Nis Nissen
Maxwell Sehested
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onxeo DK
Original Assignee
Onxeo DK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onxeo DK filed Critical Onxeo DK
Publication of AU2009220942A1 publication Critical patent/AU2009220942A1/en
Publication of AU2009220942A8 publication Critical patent/AU2009220942A8/en
Application granted granted Critical
Publication of AU2009220942B2 publication Critical patent/AU2009220942B2/en
Assigned to ONXEO DK, BRANCH OF ONXEO S.A., FRANCE reassignment ONXEO DK, BRANCH OF ONXEO S.A., FRANCE Request for Assignment Assignors: TOPOTARGET A/S
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2009220942A 2008-03-07 2009-03-06 Methods of treatment employing prolonged continuous infusion of Belinostat Active AU2009220942B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3463508P 2008-03-07 2008-03-07
US61/034,635 2008-03-07
PCT/IB2009/005044 WO2009109861A1 (en) 2008-03-07 2009-03-06 Methods of treatment employing prolonged continuous infusion of belinostat

Publications (3)

Publication Number Publication Date
AU2009220942A1 AU2009220942A1 (en) 2009-09-11
AU2009220942A8 AU2009220942A8 (en) 2012-08-30
AU2009220942B2 true AU2009220942B2 (en) 2015-05-28

Family

ID=40691318

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009220942A Active AU2009220942B2 (en) 2008-03-07 2009-03-06 Methods of treatment employing prolonged continuous infusion of Belinostat

Country Status (14)

Country Link
US (1) US20110003777A1 (cg-RX-API-DMAC10.html)
EP (1) EP2262493B1 (cg-RX-API-DMAC10.html)
JP (1) JP5615189B2 (cg-RX-API-DMAC10.html)
CN (1) CN102083428A (cg-RX-API-DMAC10.html)
AU (1) AU2009220942B2 (cg-RX-API-DMAC10.html)
CA (1) CA2717207A1 (cg-RX-API-DMAC10.html)
DK (1) DK2262493T3 (cg-RX-API-DMAC10.html)
EA (1) EA022880B1 (cg-RX-API-DMAC10.html)
ES (1) ES2536208T3 (cg-RX-API-DMAC10.html)
MX (1) MX2010009642A (cg-RX-API-DMAC10.html)
PL (1) PL2262493T3 (cg-RX-API-DMAC10.html)
PT (1) PT2262493E (cg-RX-API-DMAC10.html)
SI (1) SI2262493T1 (cg-RX-API-DMAC10.html)
WO (1) WO2009109861A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064663A1 (en) 2009-11-25 2011-06-03 Festuccia, Claudio Combination treatment employing belinostat and bicalutamide
MX357935B (es) * 2012-04-27 2018-07-31 Sun Pharmaceutical Ind Ltd Solución de gemcitabina lista para infundir.
CN103839548B (zh) * 2012-11-26 2018-06-01 腾讯科技（北京）有限公司 一种语音交互方法、装置、系统和移动终端

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025921A1 (en) * 1999-07-26 2002-02-28 Petito George D. Composition and method for growing, protecting, and healing tissues and cells
WO2006120456A1 (en) * 2005-05-13 2006-11-16 Topotarget Uk Limited Pharmaceutical formulations of hdac inhibitors

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642316A (en) * 1985-05-20 1987-02-10 Warner-Lambert Company Parenteral phenytoin preparations
US6071923A (en) * 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
WO2000021979A2 (en) * 1998-10-13 2000-04-20 Fujisawa Pharmaceutical Co., Ltd. Cyclic tetrapeptide and their use as histone deacetylase inhibitor
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
KR20100035666A (ko) * 1999-11-23 2010-04-05 메틸진 인크. 히스톤 디아세틸라제의 억제제
CA2423868C (en) * 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
EP2292593A3 (en) * 2000-09-29 2011-05-25 TopoTarget UK Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
WO2002074298A1 (en) * 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Il-6 production inhibitors
MXPA04001253A (es) * 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
US6897220B2 (en) * 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
RU2301666C2 (ru) * 2002-01-11 2007-06-27 Маттиас Рат Обладающий питательными свойствами фармацевтический состав на основе полифенолов и его использование при лечении рака
US20030235588A1 (en) * 2002-02-15 2003-12-25 Richon Victoria M. Method of treating TRX mediated diseases
US20050288227A1 (en) * 2002-02-15 2005-12-29 Marks Paul A Use of thioredoxin measurements for diagnostics and treatments
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
MXPA04008577A (es) * 2002-03-04 2005-07-13 Aton Pharma Inc Metodos para inducir diferenciacion terminal.
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
WO2003087066A1 (en) * 2002-04-11 2003-10-23 Sk Chemicals, Co., Ltd. α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS
JP2005530734A (ja) * 2002-04-15 2005-10-13 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 癌の処置のための併用療法
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
WO2004064727A2 (en) * 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
US7375228B2 (en) * 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
HRP20060080A2 (en) * 2003-08-26 2006-07-31 Sloan-Kettering Institute For Cancer Research Method of treating cancer with hdac inhibitors
WO2005052143A2 (de) * 2003-11-14 2005-06-09 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
EP1689445B1 (de) * 2003-11-14 2015-02-25 Per Sonne Holm Neue verwendung von adenoviren und dafür codierende nukleinsäuren
GB0401876D0 (en) * 2004-01-28 2004-03-03 Vereniging Het Nl Kanker I New use for cancer antigen
CA2557568C (en) * 2004-02-27 2014-05-27 Jane Trepel Pharmacodynamic assays using flow cytometry
EP1591109B1 (en) * 2004-04-30 2008-07-02 TopoTarget Germany AG Formulation comprising histone deacetylase inhibitor exhibiting biphasic release
WO2006014024A1 (ja) * 2004-08-06 2006-02-09 Ono Pharmaceutical Co., Ltd. 精神神経系疾患治療剤
CN101001851B (zh) * 2004-08-09 2011-04-20 安斯泰来制药有限公司 具有作为组蛋白脱乙酰酶(hdac)抑制剂的活性的羟基酰胺化合物
US8889742B2 (en) * 2004-11-30 2014-11-18 The Trustees Of The University Of Pennsylvania Use of HDAC and/or DNMT inhibitors for treatment of ischemic injury
US20090232800A1 (en) * 2004-12-31 2009-09-17 Per Sonne Holm E1-minus adenoviruses and use thereof
EP1845973B1 (en) * 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
NZ589276A (en) * 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
US20060229237A1 (en) * 2005-04-07 2006-10-12 Yih-Lin Chung Treatment of gastrointestinal distress
GB0509225D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
EP1743654A1 (en) * 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
AU2006283677A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
CA2621406A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. Pparactive compounds
CA2627923C (en) * 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8530493B2 (en) * 2006-02-22 2013-09-10 4Sc Ag Indolopyridines as Eg5 kinesin modulators
AU2007217562A1 (en) * 2006-02-22 2007-08-30 4Sc Ag Indolopyridines as EG5 kinesin modulators
EP1839656A1 (en) * 2006-03-31 2007-10-03 TopoTarget Germany AG Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
US20090142337A1 (en) * 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
WO2007146234A2 (en) * 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
US8338482B2 (en) * 2006-07-20 2012-12-25 Wisconsin Alumni Research Foundation Modulating notch1 signaling pathway for treating neuroendocrine tumors
US20080242648A1 (en) * 2006-11-10 2008-10-02 Syndax Pharmaceuticals, Inc., A California Corporation COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
US7915245B2 (en) * 2007-02-01 2011-03-29 The Board Of Regents Of The University Of Texas System Methods and compositions of trail-death receptor agonists/activators
WO2008101121A2 (en) * 2007-02-14 2008-08-21 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by muc1 and klf proteins
WO2008136838A1 (en) * 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
GB2454118B (en) * 2007-06-06 2010-06-02 Univ Maryland Hdac inhibitors and hormone targeted drugs for the treatment of cancer
WO2009146034A2 (en) * 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
WO2009137649A2 (en) * 2008-05-07 2009-11-12 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025921A1 (en) * 1999-07-26 2002-02-28 Petito George D. Composition and method for growing, protecting, and healing tissues and cells
WO2006120456A1 (en) * 2005-05-13 2006-11-16 Topotarget Uk Limited Pharmaceutical formulations of hdac inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STEELE, N.L. et al., 'A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor Belinostat in patients with advanced solid tumors', 2008, Clinical Cancer Research, vol. 14, pages 804-810 *

Also Published As

Publication number Publication date
EA201070913A1 (ru) 2011-04-29
AU2009220942A8 (en) 2012-08-30
JP5615189B2 (ja) 2014-10-29
EA022880B1 (ru) 2016-03-31
DK2262493T3 (en) 2015-04-27
HK1152247A1 (en) 2012-02-24
AU2009220942A1 (en) 2009-09-11
PL2262493T3 (pl) 2015-08-31
EP2262493A1 (en) 2010-12-22
WO2009109861A1 (en) 2009-09-11
ES2536208T3 (es) 2015-05-21
EP2262493B1 (en) 2015-02-25
US20110003777A1 (en) 2011-01-06
SI2262493T1 (sl) 2015-07-31
PT2262493E (pt) 2015-06-02
JP2011513378A (ja) 2011-04-28
CA2717207A1 (en) 2009-09-11
CN102083428A (zh) 2011-06-01
MX2010009642A (es) 2010-09-22

Similar Documents

Publication Publication Date Title
JP6360438B2 (ja) 癌の治療
US12325705B2 (en) Small molecules for the treatment of primary cancer and cancer metastasis
KR20150063070A (ko) 벨리노스타트 및 트라벡테딘을 사용한 병용 요법
US20250367229A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
US20250313531A1 (en) Formulated and/or Co-Formulated Liposome Compositions Containing IDO Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof
JP5642892B2 (ja) 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤
TW202038932A (zh) 使用6,8-雙-苄硫基-辛酸和自噬抑制劑治療癌症之治療方法及組成物
CN109498627A (zh) 一种治疗肿瘤的药物组合物及其应用
EP2262493B1 (en) Methods of treatment employing prolonged continuous infusion of belinostat
BRPI0821739B1 (pt) sistema de liberação de droga para administração de uma substância anfifílica catiônica farmaceuticamente ativa compreendendo nanopartículas, composição farmacêutica e método de preparação de sistema de liberação de droga
WO2011064663A1 (en) Combination treatment employing belinostat and bicalutamide
JP2022515171A (ja) ６，８－ビス－ベンジルチオ－オクタン酸および自食作用阻害剤を使用して癌を治療するための治療方法および組成物
HK1152247B (en) Methods of treatment employing prolonged continuous infusion of belinostat
US20080064665A1 (en) Combination approaches to cancer treatment
HK1240937A1 (en) Small molecules for the treatment of primary cancer and cancer metastasis
KR101327904B1 (ko) 목시플록사신 염산염의 주사제형
WO2008033039A1 (en) Cancer treatment

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 24 , NO 38 , PAGE(S) 4433 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME TOPOTARGET A/S, APPLICATION NO. 2009220942, UNDER INID (71) CORRECT THE NAME TO TOPOTARGET A/S

PC1 Assignment before grant (sect. 113)

Owner name: ONXEO DK, BRANCH OF ONXEO S.A., FRANCE

Free format text: FORMER APPLICANT(S): TOPOTARGET A/S

FGA Letters patent sealed or granted (standard patent)